FI45048C - Förfarande för framställning av antranilsyraderivat med analgetisk och /eller inflammationshindrande verkan. - Google Patents

Förfarande för framställning av antranilsyraderivat med analgetisk och /eller inflammationshindrande verkan.

Info

Publication number
FI45048C
FI45048C FI653001A FI300165A FI45048C FI 45048 C FI45048 C FI 45048C FI 653001 A FI653001 A FI 653001A FI 300165 A FI300165 A FI 300165A FI 45048 C FI45048 C FI 45048C
Authority
FI
Finland
Prior art keywords
analgesic
preparation
acid derivatives
anthranilic acid
inflammatory action
Prior art date
Application number
FI653001A
Other languages
English (en)
Finnish (fi)
Other versions
FI45048B (sv
Inventor
Matter Max
Staehelin Fritz Rudolf
Original Assignee
Haco A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haco A G filed Critical Haco A G
Publication of FI45048B publication Critical patent/FI45048B/fi
Application granted granted Critical
Publication of FI45048C publication Critical patent/FI45048C/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Laminated Bodies (AREA)
  • Shaping By String And By Release Of Stress In Plastics And The Like (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI653001A 1964-12-15 1965-12-14 Förfarande för framställning av antranilsyraderivat med analgetisk och /eller inflammationshindrande verkan. FI45048C (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1616164A CH451945A (de) 1964-12-15 1964-12-15 Verfahren zur Herstellung von neuen N-Pyrimidylanthranilsäuren

Publications (2)

Publication Number Publication Date
FI45048B FI45048B (sv) 1971-11-30
FI45048C true FI45048C (sv) 1972-03-10

Family

ID=4414930

Family Applications (1)

Application Number Title Priority Date Filing Date
FI653001A FI45048C (sv) 1964-12-15 1965-12-14 Förfarande för framställning av antranilsyraderivat med analgetisk och /eller inflammationshindrande verkan.

Country Status (14)

Country Link
US (1) US3361749A (sv)
AT (1) AT256854B (sv)
BE (1) BE673707A (sv)
BR (1) BR6575691D0 (sv)
CH (1) CH451945A (sv)
DE (1) DE1545978A1 (sv)
DK (1) DK117835B (sv)
ES (1) ES320729A1 (sv)
FI (1) FI45048C (sv)
FR (2) FR1469035A (sv)
GB (1) GB1132244A (sv)
IL (1) IL24797A (sv)
NL (2) NL6516326A (sv)
NO (1) NO117424B (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH448083A (de) * 1963-05-04 1967-12-15 Ciba Geigy Verwendung von neuen Hydroxyaryl-pyrimidinen bei Verfahren zum Schützen von nicht-textilen organischen Materialien
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
US8101625B2 (en) * 2005-10-21 2012-01-24 Exelixis, Inc. Pyrimidinones as Casein Kinase II (CK2) modulators
UA100846C2 (uk) 2006-12-08 2013-02-11 Айерем Елелсі Сполуки та композиція як інгібітори протеїнкінази
LU92852B1 (en) * 2015-10-20 2017-05-02 Athanasios Spathis NURR1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinsons disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971307A (en) * 1961-03-02 1964-09-30 Wellcome Found 5-anilinopyrimidines

Also Published As

Publication number Publication date
ES320729A1 (es) 1966-05-16
FI45048B (sv) 1971-11-30
BE673707A (sv) 1966-04-01
FR5213M (sv) 1967-07-03
DK117835B (da) 1970-06-08
DE1545978A1 (de) 1969-12-11
IL24797A (en) 1969-11-12
NO117424B (sv) 1969-08-11
BR6575691D0 (pt) 1973-09-06
AT256854B (de) 1967-09-11
GB1132244A (en) 1968-10-30
NL6516326A (sv) 1966-06-16
NL129020C (sv)
CH451945A (de) 1968-05-15
US3361749A (en) 1968-01-02
FR1469035A (fr) 1967-02-10

Similar Documents

Publication Publication Date Title
FI45953C (sv) Förfarande för framställning av (3-bensoyl-fenyl)-ättiksyraderivat.
FI49302C (sv) Förfarande för framställning av koronarutvidgande N6-bensyl-adenosin-d erivat.
DK132411B (da) Analogifremgangsmåde til fremstilling af pyrrylaminoketonderivater eller syreadditionssalte deraf.
FI45048C (sv) Förfarande för framställning av antranilsyraderivat med analgetisk och /eller inflammationshindrande verkan.
FI46154C (sv) Förfarande för framställning av terapeutiskt användbara diaminobentsof enoner och deras syraadditionssalter.
FI49408C (sv) Förfarande för framställning av terapeutiskt användbara 1-fenoximetyl- 3,4-dihydro- eller 1,2,3,4-tetrahydroisokinolinderivat och deras salte r.
FI51587C (sv) Förfarande för framställning av sulfamyl-m-aminobensoesyror med terape utisk verkan.
FI47489C (sv) Förfarande för framställning av inflammationsförhindrande 5-(1-aroyl-3 -indolyl-metyl)-tetrazoler.
FI49612C (sv) Förfarande för framställning av farmakologiskt värdefulla aryloxiisoal kyl-delta2-imidazolinderivat och syraadditonssalter därav.
FI47185C (sv) Förfarande för framställning av 1-p-klorbensoyl-2-metyl-5-metoxi-indol -3-etanol med inflammationsförhindrande antipyretisk och analgetisk ve rkan.
FI44002C (fi) Menetelmä tulehduksenvastaisten, kivuntunnetta poistavien ja kuumetta lievittävien, substituoitujen malonihappohydratsidien valmistamiseksi
FI46727C (sv) Förfarande för framställning av pyridazolderivat.
DK120392B (da) Analogifremgangsmåde til fremstilling af quinazolinderivater.
FI49023C (sv) Förfarande för framställning av nya difenylaminderivat användbara såso m antiinflammatoriska och feberstillande läkemedel.
FI49162C (sv) Förfarande för framställning av terapeutiskt användbara 3-indolyl-alif atisk-syra-derivat.
FI45045C (sv) Förfarande för framställning av nya terapeutiskt verksamma 5-nitro-2-f uryl-isoxazolderivat.
FI49033C (sv) Analogiförfarande för framställning av kinolylformiminoetrar och deras syraadditionssalter.
FI49030C (sv) Förfarande för framställning av såsom antiinflammatoriska, feberfördri vande och smärtstillande läkemedel användbara 3-indolyl-alafatisk-syra derivat.
FI37035A (fi) Menetelmä antraniilihappojohdannaisten valmistamiseksi
FI49031C (sv) Förfarande för framställning av nya 1-acyl-3-indolyl-alifatisk-syra-de rivat användbara såsom febernedsättande, smärtstillande och antiinflam matoriska läkemedel.
FI44229C (fi) Menetelmä analgeettisten beeta-tyydyttämättömien-beeta-hydroksi-beeta-fenyylietyyliamiinien ja niiden happoadditiosuolojen valmistamiseksi
FI46947C (sv) Förfarande för framställning av aminoalkyliden substituerade 9,10-dihy droantracener och dessas syraadditionssalter
FI48081C (sv) Förfarande för framställning av farmakologiskt aktiva 1-sulfanilyl-2-i mino-3-R-imidazolidiner
FI42561C (fi) Förfarande för framställning av farmakologiskt aktiva i 6-ställningen substituerade morfantrinider
FI45448C (sv) Förfarande för framställning av terapeutiskt värdefulla pyrimidinderiv at